Biohit Oyj and Akeso to sign an Acetium distribution agreement in Russia
Biohit Oyj Biohit Oyj Press Release February 17, 2015 at 1:00 p.m. local time (EET)
Biohit Oyj has signed a distribution agreement with Akeso Pharmaceuticals. The agreement is effective immediately and Akeso gains exclusive rights for the distribution of Acetium® capsules in Russian Federation.
Acetium capsules efficiently bind (neutralize) carcinogenic acetaldehyde in an achlorhydric stomach. This contributes to the prevention of cancer in the mouth, stomach and oesophagus. Acetium capsules are intended e.g. for PPI users and persons suffering from an achlorhydric stomach caused by atrophy of the gastric mucosa and functional disorder (atrophic gastritis). An anacidic stomach is the most significant risk factor for stomach and oesophageal cancer (1).
Clinical trials with Acetium® capsule for prevention of migraine-type headache and the treatment of atrophic gastritis are ongoing.
CEO Semi Korpela, Biohit Oyj: ‘We are pleased to partner with Akeso Pharmaceuticals in order to introduce acetaldehyde binding capsules to the Russian markets as soon as the registration procedures are completed.’
Managing Director Imran Mir, Akeso Pharmaceuticals: ’We are very glad to have the opportunity to start business with the highly-talented Biohit team. I´m sure that together we will be successful in introducing Biohit´s innovative and valuable products into Russian market. ‘
Reference:
(1) Sipponen P et al (1985) Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985;35:173–177.
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Attachment: Additional information
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
Akeso in brief
Akeso is a pharmaceutical company marketing and distributing anti TB, anti infectious and anti cancer drugs in Russian Federation. We provide wide range of different services and supply products for healthcare by establishing and maintaining effective cooperation with the specialized agencies, governmental health organizations, professional groups, and other organizations as may be deemed appropriate. www.akeso.ru